Onychomycosis: a compendium of facts and a clinical experience (Q33721371)

28 July 2017

1 reference

title

Onychomycosis: a compendium of facts and a clinical experience (English)

1 reference

28 July 2017

Schlefman BS

1

1 reference

28 July 2017

publication date

1 July 1999

1 reference

Journal of Foot and Ankle Surgery

28 July 2017

published in

1 reference

28 July 2017

volume

38

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

290-302

1 reference

Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

New drugs for the nail fungus prevalent in elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

New therapies for onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Traditional management of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Current management of onychomycosis. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Antifungal agents: an overview. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Treatment of Candida nail infection with terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: A multicenter study with 36 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Superficial white onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Yellow nail syndrome and onychomycosis. Experience with itraconazole pulse therapy combined with vitamin E

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Oral therapeutic agents in fungal nail disease

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Medicine taking in Southampton: a second look

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Terbinafine in onychomycosis with involvement by non-dermatophytic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Terbinafine: An oral and topical antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Itraconazole in onychomycosis: intermittent dose schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day--a double-blind comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Onychomycosis treated with a short course of oral terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Open randomized comparison of itraconazole versus terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Once-weekly fluconazole in the treatment of onychomycosis: introduction

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail

1 reference

https://api.crossref.org/works/10.1016%2FS1067-2516%2899%2980072-6

7 January 2021

10.1016/S1067-2516(99)80072-6

Identifiers

DOI

1 reference

28 July 2017

1 reference